JP2018523687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523687A5 JP2018523687A5 JP2018508748A JP2018508748A JP2018523687A5 JP 2018523687 A5 JP2018523687 A5 JP 2018523687A5 JP 2018508748 A JP2018508748 A JP 2018508748A JP 2018508748 A JP2018508748 A JP 2018508748A JP 2018523687 A5 JP2018523687 A5 JP 2018523687A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- fibrosis
- pharmaceutical composition
- syndrome
- familial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 18
- 208000020832 chronic kidney disease Diseases 0.000 claims 16
- 208000035690 Familial cold urticaria Diseases 0.000 claims 14
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 8
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 8
- 206010016654 Fibrosis Diseases 0.000 claims 8
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 8
- 206010072219 Mevalonic aciduria Diseases 0.000 claims 8
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 8
- 206010042953 Systemic sclerosis Diseases 0.000 claims 8
- 201000008937 atopic dermatitis Diseases 0.000 claims 8
- 230000001684 chronic effect Effects 0.000 claims 8
- 201000000523 end stage renal failure Diseases 0.000 claims 8
- 230000004761 fibrosis Effects 0.000 claims 8
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 8
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims 8
- 201000006417 multiple sclerosis Diseases 0.000 claims 8
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 8
- 208000011580 syndromic disease Diseases 0.000 claims 8
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 claims 6
- 201000003883 Cystic fibrosis Diseases 0.000 claims 6
- 201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 claims 6
- 208000019693 Lung disease Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 6
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims 6
- 206010003246 arthritis Diseases 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 201000002491 encephalomyelitis Diseases 0.000 claims 6
- 208000033286 epidermolytic ichthyosis Diseases 0.000 claims 6
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 claims 5
- 229960004590 diacerein Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000033116 Asbestos intoxication Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 4
- 208000009137 Behcet syndrome Diseases 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 206010010741 Conjunctivitis Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 208000001490 Dengue Diseases 0.000 claims 4
- 206010012310 Dengue fever Diseases 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 206010012434 Dermatitis allergic Diseases 0.000 claims 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims 4
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims 4
- 208000007530 Essential hypertension Diseases 0.000 claims 4
- 201000005569 Gout Diseases 0.000 claims 4
- 208000033892 Hyperhomocysteinemia Diseases 0.000 claims 4
- 206010058490 Hyperoxia Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 4
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 4
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 4
- 108091008099 NLRP3 inflammasome Proteins 0.000 claims 4
- 208000000592 Nasal Polyps Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 4
- 206010037660 Pyrexia Diseases 0.000 claims 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims 4
- 201000010001 Silicosis Diseases 0.000 claims 4
- 206010042496 Sunburn Diseases 0.000 claims 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 4
- 206010046851 Uveitis Diseases 0.000 claims 4
- 206010047642 Vitiligo Diseases 0.000 claims 4
- 208000008526 Wells syndrome Diseases 0.000 claims 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 4
- 206010000496 acne Diseases 0.000 claims 4
- 206010000891 acute myocardial infarction Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 201000009961 allergic asthma Diseases 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 201000010105 allergic rhinitis Diseases 0.000 claims 4
- 206010003441 asbestosis Diseases 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 208000010247 contact dermatitis Diseases 0.000 claims 4
- 208000025729 dengue disease Diseases 0.000 claims 4
- 230000002500 effect on skin Effects 0.000 claims 4
- 208000028208 end stage renal disease Diseases 0.000 claims 4
- 230000003176 fibrotic effect Effects 0.000 claims 4
- 206010061989 glomerulosclerosis Diseases 0.000 claims 4
- 230000003225 hyperhomocysteinemia Effects 0.000 claims 4
- 230000000222 hyperoxic effect Effects 0.000 claims 4
- 230000009610 hypersensitivity Effects 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 206010023332 keratitis Diseases 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 201000004792 malaria Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 208000016366 nasal cavity polyp Diseases 0.000 claims 4
- 230000000737 periodic effect Effects 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 4
- 201000002793 renal fibrosis Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 230000037380 skin damage Effects 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000003926 Myelitis Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 210000001367 artery Anatomy 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 208000002849 chondrocalcinosis Diseases 0.000 claims 2
- 206010021198 ichthyosis Diseases 0.000 claims 2
- 230000000366 juvenile effect Effects 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000009240 nasopharyngitis Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021083646A JP2021121605A (ja) | 2015-08-17 | 2021-05-18 | Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ |
| JP2023045240A JP2023078360A (ja) | 2015-08-17 | 2023-03-22 | Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206102P | 2015-08-17 | 2015-08-17 | |
| US62/206,102 | 2015-08-17 | ||
| PCT/US2016/047272 WO2017031161A1 (en) | 2015-08-17 | 2016-08-17 | Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083646A Division JP2021121605A (ja) | 2015-08-17 | 2021-05-18 | Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523687A JP2018523687A (ja) | 2018-08-23 |
| JP2018523687A5 true JP2018523687A5 (https=) | 2019-09-19 |
| JP6887987B2 JP6887987B2 (ja) | 2021-06-16 |
Family
ID=58051269
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508748A Active JP6887987B2 (ja) | 2015-08-17 | 2016-08-17 | Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ |
| JP2021083646A Pending JP2021121605A (ja) | 2015-08-17 | 2021-05-18 | Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ |
| JP2023045240A Pending JP2023078360A (ja) | 2015-08-17 | 2023-03-22 | Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083646A Pending JP2021121605A (ja) | 2015-08-17 | 2021-05-18 | Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ |
| JP2023045240A Pending JP2023078360A (ja) | 2015-08-17 | 2023-03-22 | Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10195170B2 (https=) |
| EP (2) | EP3337782A4 (https=) |
| JP (3) | JP6887987B2 (https=) |
| KR (1) | KR20180037261A (https=) |
| CN (1) | CN108349867B (https=) |
| AU (2) | AU2016308121A1 (https=) |
| BR (1) | BR112018003212A2 (https=) |
| CA (1) | CA2994987C (https=) |
| IL (1) | IL257379A (https=) |
| MX (1) | MX2018002049A (https=) |
| RU (1) | RU2729066C2 (https=) |
| TW (1) | TWI743047B (https=) |
| WO (1) | WO2017031161A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| EP3562506A4 (en) | 2016-12-29 | 2021-01-06 | University of Miami | METHOD TO MODULATE INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG |
| CN110177547B (zh) | 2017-01-18 | 2022-09-27 | 台睿生物科技股份有限公司 | 用于治疗炎症性肠病和肠结肠炎的组合物 |
| WO2018225018A1 (en) | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| JP2020530472A (ja) * | 2017-08-11 | 2020-10-22 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | シュニッツラー症候群の治療方法 |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| WO2020010273A1 (en) | 2018-07-03 | 2020-01-09 | University Of Miami | Compositions and methods for treating inflammasome related diseases or conditions |
| KR102075724B1 (ko) * | 2018-09-14 | 2020-02-10 | 한국원자력의학원 | 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도 |
| IL283127B1 (en) | 2018-11-14 | 2026-02-01 | Smilebiotek Zhuhai Ltd | Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders |
| ES2975968T3 (es) * | 2018-12-03 | 2024-07-18 | Smilebiotek Zhuhai Ltd | Galato de octilo y ésteres del mismo para uso en el tratamiento y prevención de la degeneración macular asociada a la edad causada por Bacillus Megaterium |
| EA202191968A1 (ru) | 2019-01-14 | 2021-11-16 | Кадила Хелзкэр Лимитед | Новые замещенные производные сульфонилмочевины |
| CN109833292A (zh) * | 2019-02-23 | 2019-06-04 | 河南省人民医院 | 一种双醋瑞因滴眼液及其用途 |
| US20220220480A1 (en) | 2019-04-17 | 2022-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders |
| CN110179865A (zh) * | 2019-06-26 | 2019-08-30 | 广州中医药大学(广州中医药研究院) | 一种大黄蒽醌类成分的制备方法及其应用 |
| CN110787157A (zh) * | 2019-11-27 | 2020-02-14 | 中南民族大学 | 双醋瑞因在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用 |
| JP7072260B2 (ja) * | 2019-12-27 | 2022-05-20 | 国立大学法人愛媛大学 | マックル・ウェルズ症候群の治療用医薬組成物 |
| JP7459298B2 (ja) * | 2020-01-06 | 2024-04-01 | シーサン・セラピューティクス | 細胞透過性核酸複合体を有効成分として含有する黄斑変性の予防又は治療用組成物 |
| CN111358950A (zh) * | 2020-03-20 | 2020-07-03 | 厦门大学 | Caspase-1及ASC/Caspase-8作为靶点的应用 |
| WO2021198511A1 (en) | 2020-04-03 | 2021-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of sars-cov-2 infection |
| WO2022008597A1 (en) | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of infectious diseases |
| WO2022084300A1 (en) | 2020-10-20 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and monitoring form of coronavirus infection |
| CN115616216B (zh) * | 2021-07-15 | 2025-08-12 | 华南理工大学 | 抑制或阻断faah与nlrp3之间相互作用的制剂的用途 |
| WO2024261302A1 (en) | 2023-06-22 | 2024-12-26 | Institut National de la Santé et de la Recherche Médicale | Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020128317A1 (en) | 2001-01-23 | 2002-09-12 | Laboratories Negma | Treatment of pathological conditions characterized by an increased IL-1 level |
| FR2842738B1 (fr) * | 2002-07-23 | 2006-02-10 | Negma Lerads | Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus |
| GB0404953D0 (en) * | 2004-03-04 | 2004-04-07 | Arakis Ltd | Pro-drugs |
| EP2300000A1 (en) * | 2008-07-03 | 2011-03-30 | University of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| TWI473610B (zh) * | 2008-10-28 | 2015-02-21 | Twi Biotechnology Inc | 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物 |
| CN102060809B (zh) * | 2009-05-01 | 2015-05-20 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种大黄酸衍生物及其制备和用途 |
| NZ602583A (en) * | 2010-04-08 | 2014-10-31 | Twi Biotechnology Inc | Methods of using diacerein as an adjunctive therapy for diabetes |
| WO2012013670A1 (en) * | 2010-07-29 | 2012-02-02 | University Of Geneva | Process for the esterification of hyaluronic acid with hydrophobic organic compounds |
| WO2012125359A1 (en) * | 2011-03-11 | 2012-09-20 | Twi Biotechnology, Inc. | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia |
| WO2013007763A1 (en) * | 2011-07-12 | 2013-01-17 | Universität Zürich | MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE |
| US8652540B2 (en) * | 2012-06-04 | 2014-02-18 | Hong Kong Baptist University | Method of using rhein for treating fibrotic conditions and tumors |
| CN103110617A (zh) * | 2013-03-22 | 2013-05-22 | 中国人民解放军肾脏病研究所 | 一种双醋瑞因在制备治疗糖尿病肾病药物中的用途 |
| KR101486147B1 (ko) * | 2013-07-09 | 2015-01-23 | 주식회사 엘지생활건강 | Tslp 분비 저해능 및 이에 의한 알러지성 질환의 개선능을 가지는 조성물 |
| HK1249057A1 (zh) * | 2015-07-01 | 2018-10-26 | 安成生物科技股份有限公司 | 双醋瑞因或大黄酸局部用制剂及其用途 |
-
2016
- 2016-08-17 BR BR112018003212-3A patent/BR112018003212A2/en not_active Application Discontinuation
- 2016-08-17 US US15/238,950 patent/US10195170B2/en active Active
- 2016-08-17 CN CN201680048207.3A patent/CN108349867B/zh active Active
- 2016-08-17 EP EP16837725.7A patent/EP3337782A4/en not_active Withdrawn
- 2016-08-17 EP EP22204951.2A patent/EP4147694A1/en not_active Withdrawn
- 2016-08-17 KR KR1020187006526A patent/KR20180037261A/ko not_active Ceased
- 2016-08-17 CA CA2994987A patent/CA2994987C/en active Active
- 2016-08-17 RU RU2018109237A patent/RU2729066C2/ru active
- 2016-08-17 TW TW105126278A patent/TWI743047B/zh active
- 2016-08-17 MX MX2018002049A patent/MX2018002049A/es unknown
- 2016-08-17 AU AU2016308121A patent/AU2016308121A1/en not_active Abandoned
- 2016-08-17 WO PCT/US2016/047272 patent/WO2017031161A1/en not_active Ceased
- 2016-08-17 JP JP2018508748A patent/JP6887987B2/ja active Active
-
2018
- 2018-02-06 IL IL257379A patent/IL257379A/en unknown
-
2021
- 2021-01-11 AU AU2021200117A patent/AU2021200117B2/en not_active Ceased
- 2021-05-18 JP JP2021083646A patent/JP2021121605A/ja active Pending
-
2023
- 2023-03-22 JP JP2023045240A patent/JP2023078360A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523687A5 (https=) | ||
| RU2018109237A (ru) | Диацереин или его аналоги для ингибирования экспрессии asc, экспрессии nlrp3 и/или образования комплекса nlrp3 инфламмасом | |
| JP2018537513A5 (https=) | ||
| JP2021502323A5 (https=) | ||
| JP2011528332A5 (https=) | ||
| ME03822B (me) | Natrijumova so n-((1 ,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1 h-pirazol- 3-sulfonamida | |
| JP2012521994A5 (https=) | ||
| JP2017222722A5 (https=) | ||
| WO2015187542A8 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| JP2011509303A5 (https=) | ||
| NZ719360A (en) | Preparation, uses and solid forms of obeticholic acid | |
| ECSP055768A (es) | Derivados de azol-pirimidina condensados | |
| JP2015517489A5 (https=) | ||
| MX2010001400A (es) | Metodo para tratar enfermedades mediadas cxcr3 usando piperazinas heterociclicas sustituidas. | |
| JP2016510045A5 (https=) | ||
| JP2016065042A5 (https=) | ||
| BR0317885A (pt) | Composto, isÈmeros s e r enantiomericamente puros do mesmo, composição farmacêutica e métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa, de tratar ou prevenir mds, de tratar doença mieloproliferativa, angiogênese indesejada, câncer, uma doença, inflamação dos pulmões, depressão, distúrbio pulmonar obstrutivo crÈnico, doença inflamatória do intestino, dermatite atópica, psorìase, doença de crohn, artrite reumatóide, asma, eslcerose múltipla e doença cardìaca em um mamìfero e de tratar, prevenir ou controlar a sìndrome de dor regional complexa | |
| JP2015010091A5 (https=) | ||
| EA200100124A1 (ru) | Замещенные 1,8-нафтиридин-4(1h)-оны в качестве ингибиторов фосфодиэстеразы 4 | |
| JP2017531033A5 (https=) | ||
| JP2014527040A5 (https=) | ||
| BR112014008412A2 (pt) | derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral | |
| JP2017522348A5 (https=) | ||
| RU2017119539A (ru) | Новая терапия транстиретин-ассоциированного амилоидоза | |
| JP2012509281A5 (https=) |